2020 TL1 Directors Group Poolside Chat #2
This summer we will have three sessions where we will have interactive conversations with leaders who will share their knowledge about career opportunities in industry, government, and NIH.
Rebecca Brown, MEd, MN, RN, PHN
Clinical and Translational Science Institute TL1 Scholar University of Minnesota - School of Nursing
CDR Alison S. Halpin, PhD
CDR Halpin has worked in CDC’s Division of Healthcare Quality Promotion since 2013, where she directs the Office of Scientific Innovation and Integration in the Clinical and Environmental Microbiology Branch. This office comprises a group of epidemiologists, laboratory scientists and bioinformaticians leveraging novel laboratory and bioinformatics applications along with molecular epidemiology to improve patient safety and public health. Specifically, this group aims to better understand, prevent, and contain healthcare-associated infections through healthcare-associated outbreak investigations, surveillance for and detection of novel antibiotic resistance mechanisms, and understanding and leveraging human and environmental microbial communities to improve patient safety. Dr. Halpin has studied the microbiome since 2004, completing her Bachelor of Science in Molecular and Cell Biology at the University of Connecticut, where she studied medicinal leech gut bacterial symbionts. She earned her doctorate from Yale University in Epidemiology of Microbial Diseases, with a focus on the relationship between the nasal microbiota and otitis media. From 2011 to 2013, she was an Epidemic Intelligence Service Officer in CDC’s Division of Foodborne, Waterborne, and Environmental Diseases
Saralyn Mark, MD
Served as the first Senior Medical Advisor to the Office on Women's Health within the Department of Health and Human Services for 11 years and to the National Aeronautics and Space Administration for 18 years. Dr. Mark was responsible for the development and analysis of initiatives and programs on emerging technologies, public health preparedness, physician workforce issues, sex and gender-based medicine and women's health on Earth and in space. As the founder, president and CEO of SolaMed Solutions, LLC, Dr. Mark currently serves as a medical and scientific policy advisor providing scientific and strategic direction for organizations and agencies including the White House Office of Science and Technology Policy and the Bill and Melinda Gates Foundation Strategic Investment Fund. She is also the founder and president of the iGIANT®, a nonprofit dedicated to accelerating the translation of research into gender/sex-specific design elements across all sectors. Dr. Mark is an alumna of the New York University School of Medicine and Barnard College of Columbia University and completed her residency, fellowships and first academic appointment at the University of California at San Francisco School of Medicine. Dr. Mark is the author of Stellar Medicine: A Journey Through the Universe of Women's Health. She has delivered over 700 lectures in the United States and abroad and made over 350 television, radio, on-line and print appearances including CNN, NBC, ABC News and The Washington Post. Dr. Mark has received many accolades and awards from the federal government and prominent medical organizations including the 2011 American Medical Women's Association Lila A. Wallis Award for Lifetime Achievement in Women's Health and the 2017 NYU School of Medicine Alumni Leadership Award
Wendy Weinberg, Ph.D.
Senior Investigator and Chief of the Laboratory of Molecular Oncology (LMO) in the Office of Biotechnology Products (OBP), Center for Drug Evaluation and Research, FDA. As Senior Investigator, Dr. Weinberg directs a laboratory program focused on identifying and characterizing molecular events driving squamous carcinogenesis, with an emphasis on the p53/p63 family of proteins and interacting pathways. As Laboratory Chief, she supervises the regulatory review work of a team of researcher-reviewers. These regulatory review responsibilities include evaluation of the product quality (chemistry, manufacturing and controls) aspect of biotechnology product submissions, from pre-submission guidance and Investigational New Drug applications through Biologic License Applications and post-marketing submissions. The products her team covers are primarily antibody-based therapies targeting oncology indications.